An international study with the participation of IDIBELL shows that the drug semaglutide, for obesity and diabetes, protects the kidney in obese people with kidney disease
The novel results have been presented at the Kidney Week 2024 Congress of the American Society of Nephrology, in San Diego, and have been published simultaneously in the prestigious journal Nature Medicine. In Spain, 40% of the population is overweight, 22% of the population is obese and 3 out of 10 patients with chronic kidney disease suffer from obesity.